{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:07:00Z","timestamp":1795036020712,"version":"4.10.2"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":39,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/24304-0"],"award-info":[{"award-number":["2017\/24304-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2022\/05199-9"],"award-info":[{"award-number":["2022\/05199-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2023\/16182-2"],"award-info":[{"award-number":["2023\/16182-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pnpbp.2026.111903","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:14:28Z","timestamp":1788452068000},"page":"111903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cannabigerol, a minor phytocannabinoid, prevents behavioral changes induced by psychotomimetic drugs"],"prefix":"10.1016","volume":"149","author":[{"given":"J.F.C.","family":"Pedrazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Sales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.C.","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.W.","family":"Zuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.S.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Del Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2026.111903_bb0005","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/biom10060947","article-title":"Brain NMDA receptors in schizophrenia and depression","volume":"10","author":"Adell","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0010","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1021\/np8002673","article-title":"Antibacterial cannabinoids from Cannabis sativa: a structure-activity study","volume":"71","author":"Appendino","year":"2008","journal-title":"J. Nat. Prod."},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111903_bb0015","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.biopsych.2011.01.027","article-title":"Catecholamine influences on dorsolateral prefrontal cortical networks","volume":"69","author":"Arnsten","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0020","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/cap.2006.0098","article-title":"Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit\/hyperactivity disorder: emerging concepts from new data","volume":"17","author":"Arnsten","year":"2007","journal-title":"J. Child Adolesc. Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0030","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/FBP.0000000000000494","article-title":"PT-31, a putative \u03b12-adrenoceptor agonist, is effective in schizophrenia cognitive symptoms in mice","volume":"30","author":"Betti","year":"2019","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0035","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.bcp.2013.01.017","article-title":"Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease","volume":"85","author":"Borrelli","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0045","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s002130100810","article-title":"Human studies of prepulse inhibition of startle: a review","volume":"156","author":"Braff","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70337","article-title":"The locus Coeruleus-noradrenergic system in the healthy and diseased brain: a narrative review","volume":"32","author":"Caestecker","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/3336516","article-title":"Pharmacological aspects and biological effects of Cannabigerol and its synthetic derivatives","volume":"2022","author":"Calapai","year":"2022","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","article-title":"Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats","volume":"199","author":"Campos","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0065","first-page":"3364","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.phrs.2016.01.033","article-title":"Cannabidiol, neuroprotection and neuropsychiatric disorders","volume":"112","author":"Campos","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1476-5381.2009.00515.x","article-title":"Evidence that the plant cannabinoid cannabigerol is a highly potent \u03b12-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist","volume":"159","author":"Cascio","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0080","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/ph17060756","article-title":"TRPV1 channels in the central nervous system as drug targets","volume":"17","author":"Chahl","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0085","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/cercor\/11.1.73","article-title":"The noradrenergic alpha2 agonist clonidine modulates behavioural and neuroanatomical correlates of human attentional orienting and alerting","volume":"11","author":"Coull","year":"2001","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0100","article-title":"Novel drug treatments for schizophrenia","author":"Coyle","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/156802607779318190","article-title":"Interest of alpha2-adrenergic agonists and antagonists in clinical practice: background, facts and perspectives","volume":"7","author":"Crassous","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-66879-0","article-title":"Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial","volume":"14","author":"Cuttler","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0115","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103575","article-title":"Antioxidant and neuroprotective effects induced by Cannabidiol and Cannabigerol in rat CTX-TNA2 astrocytes and isolated cortexes","volume":"21","author":"di Giacomo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0125","first-page":"3867","article-title":"The endocannabinoid system and its modulation by phytocannabinoids: what lies beyond Delta-9-tetrahydrocannabinol?","volume":"21","author":"Di Marzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0130","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3390\/nu11081956","article-title":"Lifestyle and metabolic syndrome: contribution of the Endocannabinoidome","volume":"11","author":"Di Marzo","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1113\/jphysiol.2006.124958","article-title":"Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block","volume":"581","author":"Dravid","year":"2007","journal-title":"J. Physiol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00008877-200006000-00006","article-title":"Animal models for the negative symptoms of schizophrenia","volume":"11","author":"Ellenbroek","year":"2000","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0145","first-page":"1","article-title":"Phytochemistry of Cannabis sativa L","volume":"103","author":"ElSohly","year":"2017","journal-title":"Prog. Chem. Org. Nat. Prod."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0014-5793(98)00450-5","article-title":"Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol","volume":"427","author":"Fellermeier","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0155","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neuropharm.2008.06.076","article-title":"Looking for the role of cannabinoid receptor heteromers in striatal function","volume":"56","author":"Ferr\u00e9","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0160","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/157488909788453031","article-title":"Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications","volume":"4","author":"Galal","year":"2009","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","article-title":"Alpha-2 adrenergic receptor agonists: a review of current clinical applications","volume":"62","author":"Giovannitti","year":"2015","journal-title":"Anesth. Prog."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0175","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyu041","article-title":"Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice","volume":"18","author":"Gomes","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0185","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.tplants.2020.05.005","article-title":"Phytocannabinoids: origins and biosynthesis","volume":"25","author":"G\u00fclck","year":"2020","journal-title":"Trends Plant Sci."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0190","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbr.2011.03.053","article-title":"Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia","volume":"222","author":"Gururajan","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00634458","article-title":"The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward","volume":"99","author":"Herberg","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0200","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III--the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjp.bp.113.138578","article-title":"A neurobiological hypothesis for the classification of schizophrenia: type a (hyperdopaminergic) and type B (normodopaminergic)","volume":"205","author":"Howes","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0210","first-page":"323","article-title":"Schizophrenia: an integrated sociodevelopmental-cognitive model","volume":"16","author":"Howes","year":"2014","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0215","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0220","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaac.2010.11.005","article-title":"Clonidine extended-release tablets for pediatric patients with attention-deficit\/hyperactivity disorder","volume":"50","author":"Jain","year":"2011","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0225","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.3390\/ijms23147929","article-title":"The origin and biomedical relevance of Cannabigerol","volume":"23","author":"Jastrz\u0105b","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0230","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/schbul\/sbs100","article-title":"Twenty-five years of glutamate in schizophrenia: are we there yet?","volume":"38","author":"Javitt","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0235","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0240","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamapsychiatry.2022.1142","article-title":"The course of general cognitive ability in individuals with psychotic disorders","volume":"79","author":"Jonas","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0245","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0250","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1073\/pnas.0407737102","article-title":"Amphetamine induces dopamine efflux through a dopamine transporter channel","volume":"102","author":"Kahlig","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0255","first-page":"449","article-title":"Altered GABA a receptor-mediated inhibition in the medial prefrontal cortex of the MK-801 model of schizophrenia","volume":"196","author":"Kehrer","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2011.01.011","article-title":"Schizophrenia, \u201cjust the facts\u201d 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse","volume":"127","author":"Keshavan","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0265","doi-asserted-by":"crossref","first-page":"8056","DOI":"10.3390\/ijms26168056","article-title":"Cannabigerol attenuates memory impairments, neurodegeneration, and Neuroinflammation caused by transient global cerebral ischemia in mice","volume":"26","author":"Kohara","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0270","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1007\/s12035-019-1596-0","article-title":"Effects of fatty acid amide hydrolase inhibitors acute administration on the positive and cognitive symptoms of schizophrenia in mice","volume":"56","author":"Kruk-Slomka","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0275","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0280","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0285","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and reverses psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0290","article-title":"Multimodal therapeutic strategies for neuropsychiatric disorders: focus on synergistic drug mechanisms","volume":"158","author":"Li","year":"2024","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0295","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0300","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/7854_2014_316","article-title":"Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle","volume":"21","author":"Light","year":"2014","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0305","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fnbeh.2017.00260","article-title":"Olanzapine reverses MK-801-induced cognitive deficits and region-specific alterations of NMDA receptor subunits","volume":"11","author":"Liu","year":"2018","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0310","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.npp.1300838","article-title":"Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice","volume":"31","author":"Long","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0315","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0893-133X(89)90035-3","article-title":"Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat","volume":"2","author":"Mansbach","year":"1989","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0320","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.neuropharm.2007.12.011","article-title":"Antagonistic cannabinoid CB(1)\/dopamine D(2) receptor interactions in striatal CB(1)\/D(2) heteromers","volume":"54","author":"Marcellino","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0325","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia-an overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0335","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pharmtox-051921-083709","article-title":"A delightful trip along the pathway of cannabinoid and endocannabinoid chemistry and pharmacology","volume":"63","author":"Mechoulam","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0345","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbr.2008.05.016","article-title":"Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?","volume":"195","author":"Meltzer","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1183019","article-title":"Cannabigerol modulates \u03b12-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat","volume":"14","author":"Mendiguren","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0355","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.162.3.495","article-title":"Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up","volume":"162","author":"Milev","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0360","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2004.01.027","article-title":"A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book","volume":"55","author":"Mishara","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0365","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0370","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0375","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2005.02.040","article-title":"Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice","volume":"512","author":"Moreira","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0380","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1124\/jpet.120.000340","article-title":"The pharmacological case for Cannabigerol","volume":"376","author":"Nachnani","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0385","article-title":"Pharmacological data of cannabidiol-and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1\/CB2 heteromer receptors","volume":"158","author":"Navarro","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0390","first-page":"332","article-title":"Cannabigerol treatment shows Antiproliferative activity and causes apoptosis of human colorectal Cancer cells","volume":"27","author":"Park","year":"2024","journal-title":"Aust. J. Pharm."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0395","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s00213-015-3945-7","article-title":"Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine","volume":"232","author":"Pedrazzi","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110352","article-title":"Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum","volume":"111","author":"Pedrazzi","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bib532","doi-asserted-by":"crossref","first-page":"173879","DOI":"10.1016\/j.pbb.2024.173879","article-title":"Cannabidiol attenuates prepulse inhibition disruption by facilitating TRPV1 and 5-HT1A receptor-mediated neurotransmission","volume":"245","author":"Pedrazzi","year":"2024","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0410","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.3390\/healthcare10122366","article-title":"Mortality in schizophrenia-Spectrum disorders: recent advances in understanding and management","volume":"10","author":"Peritogiannis","year":"2022","journal-title":"Healthcare"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0415","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cne.20881","article-title":"Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens","volume":"495","author":"Pickel","year":"2006","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0420","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0425","first-page":"706","article-title":"The neurobiology of treatment-resistant schizophrenia: unmet needs and focus on dopamine partial agonists","volume":"45","author":"Potkin","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0430","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/2589977515666230502104021","article-title":"Phytocannabinoids as potential multitargeting Neuroprotectants in Alzheimer\u2019s disease","volume":"16","author":"Rathod","year":"2024","journal-title":"Curr. Drug Res. Rev."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0435","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/PRA.0000000000000860","article-title":"Symptomatic predictors of suicidal behavior in early psychosis: systematic review","volume":"31","author":"Ricci","year":"2025","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102047","article-title":"The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination","volume":"69","author":"Robaina Cabrera","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-57369-0_1","article-title":"Constituents of Cannabis sativa","volume":"1264","author":"Rock","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0450","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-010-2157-4","article-title":"Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews","volume":"215","author":"Rock","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104749","article-title":"Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors","volume":"156","author":"Rodrigues da Silva","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0460","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pharep.2015.07.004","article-title":"The effect of combined treatment with escitalopram and risperidone on the MK-801-induced changes in the object recognition test in mice","volume":"68","author":"Rog\u00f3\u017c","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0465","first-page":"118","article-title":"Restoration of social withdrawal and recognition memory deficits induced by N-methyl-D-aspartate receptor antagonism","volume":"247","author":"Rubin","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0470","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3389\/fphar.2017.00399","article-title":"Cannabinoids and Vanilloids in schizophrenia: neurophysiological evidence and directions for basic research","volume":"28","author":"Ruggiero","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0475","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0480","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41398-022-01904-2","article-title":"Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics","volume":"12","author":"Spark","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0485","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2006.00947.x","article-title":"Negative symptoms of schizophrenia: a problem that will not go away","volume":"115","author":"Stahl","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0490","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/archpsyc.1994.03950020063007","article-title":"Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients","volume":"51","author":"Swerdlow","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0495","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/sj.npp.1300086","article-title":"Amphetamine effects on prepulse inhibition across-species: replication and parametric extension","volume":"28","author":"Swerdlow","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0500","first-page":"61","article-title":"Molecular pharmacology of Phytocannabinoids","volume":"103","author":"Turner","year":"2017","journal-title":"Prog. Chem. Org. Nat. Prod."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0505","article-title":"Modulating excitation-to-inhibition balance to preserve memory recognition and social interaction in rodent models of neuropsychiatric deficits","volume":"71","author":"Uys","year":"2017","journal-title":"Synapse"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0510","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuropharm.2011.04.001","article-title":"Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT1A receptor knockout mice: implications for schizophrenia","volume":"61","author":"van den Buuse","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111903_bib531","doi-asserted-by":"crossref","first-page":"871962","DOI":"10.3389\/fphys.2022.871962","article-title":"Acute cannabigerol administration lowers blood pressure in mice","volume":"13","author":"Vernail","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2024.173883","article-title":"Orally administered Cannabigerol (CBG) in rats: cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain","volume":"245","author":"Weerts","year":"2024","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2026.111903_bb0520","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0306-4522(85)90166-6","article-title":"Characterization of \u03b12-adrenoceptors which increase potassium conductance in rat locus Coeruleus Neurones","volume":"14","author":"Williams","year":"1985","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0525","doi-asserted-by":"crossref","first-page":"7104","DOI":"10.1073\/pnas.83.18.7104","article-title":"The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist","volume":"83","author":"Wong","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pnpbp.2026.111903_bb0530","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","article-title":"Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug","volume":"39","author":"Zuardi","year":"2006","journal-title":"Braz. J. Med. Biol. Res."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626003015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626003015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:25:11Z","timestamp":1793924711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626003015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":105,"alternative-id":["S0278584626003015"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111903","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabigerol, a minor phytocannabinoid, prevents behavioral changes induced by psychotomimetic drugs","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111903"}}